Baseline characteristics and age-related macular degeneration in participants of the “ASPirin in Reducing Events in the Elderly” (ASPREE)-AMD trial

Liubov D. Robman; Le Thi Phuong Thao; Robyn H. Guymer; Rory Wolfe; Robyn L. Woods; Lauren AB Hodgson; James Phung; Galina A. Makeyeva; Y-Anh Le-Pham; Suzanne G. Orchard; Jewhara Suleiman; Emily Maguire; Ruth E. Trevaks; Stephanie A. Ward; Moeen Riaz; Paul Lacaze; Elsdon Storey; Walter P. Abhayaratna; Mark R. Nelson; Michael E. Ernst; Christopher M. Reid; John J. McNeil; ASPREE Investigator Group

doi:10.1016/j.conctc.2020.100667

Back

Baseline characteristics and age-related macular degeneration in participants of the “ASPirin in Reducing Events in the Elderly” (ASPREE)-AMD trial

Journal article

Open access

Peer reviewed

Baseline characteristics and age-related macular degeneration in participants of the “ASPirin in Reducing Events in the Elderly” (ASPREE)-AMD trial

Liubov D. Robman, Le Thi Phuong Thao, Robyn H. Guymer, Rory Wolfe, Robyn L. Woods, Lauren AB Hodgson, James Phung, Galina A. Makeyeva, Y-Anh Le-Pham, Suzanne G. Orchard, …

Contemporary clinical trials communications, Vol.20, pp.100667-100667

12/2020

DOI: 10.1016/j.conctc.2020.100667

PMCID: PMC7658662

PMID: 33210016

Files and links (1)

url

https://doi.org/10.1016/j.conctc.2020.100667View

Published (Version of record) Open Access

Abstract

To describe the baseline participant characteristics in the ASPREE-AMD study, investigating the effect of aspirin on AMD incidence and progression. Australian participants from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, randomized to 100 mg aspirin daily or placebo, had non-mydriatic, digital color fundus images graded according to the Beckman AMD classification. Associations with AMD were determined for baseline characteristics and genetic risk variants. ASPREE-AMD sub-study enrolled 4993 participants with gradable macular images. Median age was 73.4 years (IQR, 71.5, 76.6), 52% were female, 10% had diabetes mellitus, 73% had hypertension, and 44% were former/current smokers. Early, intermediate and late AMD (detected in 20.6%, 16.1%, 1.1%, respectively), significantly associated with age, were also associated with increasing HDL levels: OR = 1.52 (95%CI, 1.26, 1.84), OR = 1.43 (1.17, 1.77) and OR = 1.96 (1.02, 3.76), respectively. Female sex was associated with early [OR = 1.37 (1.16, 1.62)], and intermediate [OR = 1.35 (1.12, 1.63)] AMD, as was previous regular use of aspirin, with OR = 1.46 (1.11, 1.92) and OR = 1.37 (1.01, 1.85), respectively. Current smoking had increased odds for late AMD, OR = 4.02 (1.42, 11.36). Genetic risk variant rs3750846 (ARMS2/HTRA1) was associated with each AMD stage (p < 0.001), risk variants rs570618 and rs10922109 (CFH) with intermediate and late AMD (p < 0.001), and rare variant rs147859257 (C3) with late AMD (p < 0.001). The randomized groups were well balanced for all analyzed AMD risk factors. Observed associations are typical of AMD. The ASPREE-AMD clinical trial provides a unique opportunity to determine the risks and benefits of low-dose aspirin for AMD incidence and progression in elderly population. Australian New Zealand Clinical Trial Registry: ACTRN 12613000755730.

Age-related macular degeneration

AMD

Aspirin

Baseline characteristics

Elderly

Randomized controlled trial

Details

Title: Subtitle: Baseline characteristics and age-related macular degeneration in participants of the “ASPirin in Reducing Events in the Elderly” (ASPREE)-AMD trial
Creators: Liubov D. Robman - Centre for Eye Research Australia
Le Thi Phuong Thao - Monash University
Robyn H. Guymer - Centre for Eye Research Australia
Rory Wolfe - Monash University
Robyn L. Woods - Monash University
Lauren AB Hodgson - Centre for Eye Research Australia
James Phung - Monash University
Galina A. Makeyeva - Centre for Eye Research Australia
Y-Anh Le-Pham - Monash University
Suzanne G. Orchard - Monash University
Jewhara Suleiman - Monash University
Emily Maguire - Monash University
Ruth E. Trevaks - Monash University
Stephanie A. Ward - Monash University
Moeen Riaz - Monash University
Paul Lacaze - Monash University
Elsdon Storey - Monash University
Walter P. Abhayaratna - Australian National University
Mark R. Nelson - University of Tasmania
Michael E. Ernst - Roy J. and Lucille A. Carver College of Medicine
Christopher M. Reid - Monash University
John J. McNeil - Monash University
ASPREE Investigator Group
Resource Type: Journal article
Publication Details: Contemporary clinical trials communications, Vol.20, pp.100667-100667
DOI: 10.1016/j.conctc.2020.100667
PMID: 33210016
PMCID: PMC7658662
NLM abbreviation: Contemp Clin Trials Commun
ISSN: 2451-8654
eISSN: 2451-8654
Publisher: Elsevier Inc
Grant note: DOI: 10.13039/100000049, name: National Institute on Aging; DOI: 10.13039/100000054, name: National Cancer Institute; DOI: 10.13039/100000002, name: National Institutes of Health, award: U01AG029824; DOI: 10.13039/501100000925, name: National Health and Medical Research Council of Australia, award: 334047, 1127060; DOI: 10.13039/501100000925, name: National Health and Medical Research Council of Australia, award: APP1051625; DOI: 10.13039/100000002, name: National Institutes of Health, award: R01EY026890
Language: English
Date published: 12/2020
Academic Unit: Family and Community Medicine; Pharmacy Practice and Science
Record Identifier: 9984297346202771

Metrics

28 Record Views

13 Times Cited - Web of Science